Mr. Hugh Rogers reports

CLARIFICATION OF PROMOTIONAL ACTIVITIES

Bionxt Solutions Inc. has clarified its news release dated Jan. 31, 2025, at the request of the Canadian Investment Regulatory Organization.

The company engaged Apaton Finance GmbH, wholly owned by Mario Hose, pursuant to which Apaton will provide to the company certain investor relations services, including, but not limited to, activities that are designed to enhance brand visibility, educate and engage stakeholders, and drive investor engagement in Germany. In particular, Apaton provides dissemination of company news releases and German translations on social media platforms and through opt-in e-mail publication. Under the terms of the agreement, Apaton will provide the services from Feb. 1, 2025, until June 30, 2025.

In consideration of the services, the company will pay Apaton a cash fee of 10,000 euros on Feb. 2, 2025, and 10,000 euros on April 1, 2025. Additionally, the company granted to Mr. Hose 50,000 options, each entitling Mr. Hose to acquire one common share at an exercise price of 50 cents per common share for a period of two years, in accordance with the option plan. Twenty-five per cent of the options granted to Mr. Hose will vest every three months following the date of grant until the date that is 12 months following the date of grant.

The company also engaged Cayo Ventures GmbH, wholly owned by Yves Toelderer, pursuant to which Cayo will provide to the company certain investor relations services, including, but not limited to, providing German language engagement through opt-in e-mail press release distribution and digital marketing services designed to drive Internet traffic to the company's website. Under the terms of the agreement, Cayo will provide the services from Feb. 1, 2025, until March 31, 2025.

In consideration of the services, the company will pay Cayo a cash fee of 20,000 euros per week; however, it may be reduced on a week-to-week basis at the discretion of the company depending on the number of trading days and other internal cash management decisions. To clarify, the company reserves the right to unilaterally reduce or stop the payments at any time for any reason. Additionally, the company granted to Mr. Toelderer 150,000 options, each entitling Mr. Toelderer to acquire one common share at an exercise price of 50 cents per common share for a period of two years, in accordance with the option plan. Twenty-five per cent of the options granted to Mr. Toelderer will vest every three months following the date of grant until the date that is 12 months following the date of grant.

The option plan was last approved by the shareholders of the company on Nov. 1, 2024.

The options and any underlying common shares in the capital of the company will be subject to a four-month-and-one-day hold period pursuant to the policies of the Canadian Securities Exchange.

About Bionxt Solutions Inc.

Bionxt is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

We seek Safe Harbor.